News | Nuclear Imaging | January 12, 2017

Bayer Recalls All of its Medrad Intego PET Infusion System Source Administration Sets

Medrad Intego PET Infusion System, recall

January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Administration Sets used in nuclear imaging. The company said particulates can form inside the vials. The U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall. The FDA said use of these devices may cause serious injuries or death.

The company is recalling all product distributed between Oct. 9, 2008 to Oct. 11, 2016. This includes 86,172 products in the U.S. 

The Medrad Intego PET Infusion System controls and delivers medications from a chamber to a patient through a needle inserted into a vein during nuclear medicine procedures. Nuclear medicine procedures are used to diagnose and treat diseases such as cancer, thyroid disease, and heart disease.

Bayer has determined all Source Administration Sets used with the Medrad Intego PET Infusion System may produce a particulate matter in the medicine vials. The particulates may be created when the tip of the needle pushes through the rubber top of the vial. If this occurs, the particulate matter could enter into the patient and cause serious adverse health consequences including infection, damage of tissue and death.

On Nov. 7, 2016, Bayer sent an urgent medical device field safety corrective action notice to all affected customers. The notice asked customers to immediately discontinue the use and quarantine any unused affected product. It further instructed customers to retain the quarantined Source Administration Sets to be used when the new qualified in-line filter is received.Customers can also contact Bayer customer care at 800.633.7231, opt. 2, to receive a returned goods authorization number and return the product to Bayer.

To see a complete list of impacted batch numbers, go to www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm536548.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Related Content

News | Nuclear Imaging

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

Home April 13, 2022
Home
Videos | Nuclear Imaging

American Society of Nuclear Cardiology (ASNC) President Dennis Calnon, M.D., MASNC, FASE, FSCCT, director of cardiac ...

Home February 01, 2022
Home
Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

Home June 02, 2021
Home
News | Nuclear Imaging

April 1, 2021 – The ability to measure myocardial blood flow (MBF) as part of myocardial perfusion imaging (MPI) is one ...

Home April 01, 2021
Home
News | Nuclear Imaging

December 4, 2020 — Spectrum Dynamics Medical, Inc., has received Canadian Medical Device License from Health Canada for ...

Home December 04, 2020
Home
News | Nuclear Imaging

September 30, 2020 — Siemens Healthineers has introduced a new version of its c.cam dedicated cardiac nuclear medicine ...

Home October 07, 2020
Home
Feature | Nuclear Imaging | Dave Fornell, Editor

There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September ...

Home November 22, 2019
Home
Videos | Nuclear Imaging

Rob Beanlands, M.D., FASNC, 2019 American Society of Nuclear Cardiology (ASNC) president, shares a couple trends he sees ...

Home November 07, 2019
Home
Videos | Nuclear Imaging

Robert C. Hendel, M.D., explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at ...

Home November 06, 2019
Home
Feature | Nuclear Imaging | Christopher A. Hanson M.D., and Jamieson M. Bourque M.D., MHS

Cardiac amyloidosis is a highly morbid and underdiagnosed infiltrative cardiomyopathy that is characterized by the ...

Home July 22, 2019
Home
Subscribe Now